Shares of RayzeBio (RYZB) jumped $30.39, or 99%, to $60.96 in pre-market trading upon the resumption of trading of the stock. Shares had been halted for news pending ahead of the company announcing Bristol Myers Squibb (BMY) will acquire RayzeBio for $62.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RYZB:
- Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
- RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Eight new option listings and one option delisting on November 8th
- RayzeBio to Participate in Upcoming Investor Conferences in November 2023
- RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors